IN8bio (NASDAQ:INAB) Trading Down 5.5%

IN8bio, Inc. (NASDAQ:INAB)’s stock price fell 5.5% during mid-day trading on Monday . The company traded as low as $0.26 and last traded at $0.27. 348,589 shares were traded during trading, an increase of 7% from the average session volume of 326,116 shares. The stock had previously closed at $0.29.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $12.50 target price on shares of IN8bio in a report on Friday, June 14th.

IN8bio Trading Down 5.5 %

The firm’s fifty day simple moving average is $0.53 and its 200 day simple moving average is $0.86. The stock has a market capitalization of $11.91 million, a P/E ratio of -0.30 and a beta of 0.01. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.66 and a current ratio of 2.66.

IN8bio (NASDAQ:INAB) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.03). As a group, equities research analysts forecast that IN8bio, Inc. will post -0.62 EPS for the current fiscal year.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.